cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mohammad Saifur Rohman
Contact Email
hsj@ub.ac.id
Phone
+628973247705
Journal Mail Official
hsj@ub.ac.id
Editorial Address
Department of Cardiology and Vascular Medicine, Dr. Saiful Anwar General Hospital, 3rd Floor CVCU Jl. Jaksa Agung Suprapto No. 2, Malang, Indonesia
Location
Kota malang,
Jawa timur
INDONESIA
Heart Science Journal
Published by Universitas Brawijaya
ISSN : 27219976     EISSN : 27219984     DOI : http://dx.doi.org/10.21776/ub.hsj.2020.001.01
Core Subject : Health, Science,
Health Professions Immunology & microbiology Medicine & Pharmacology
HEART SCIENCE is the official open access journal of Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. The journal publishes articles three times per year in January, May, and September. The journal is a peer reviewed publication and accepts articles for publication from across the world. HEART SCIENCE accepts and publishes articles in the English language only. The primary goal of this journal is to publish clinical and basic research relevant to cardiovascular medicine. The journal covers the following topics: clinical cardiology, interventional cardiology, intensive and acute cardiovascular care, vascular diseases, non-invasive cardiology, pediatric cardiology, cardiac nuclear medicine imaging, arrhythmia, cardiac prevention and rehabilitation, and cardiac surgery. Animal studies are also considered for publication in HEART SCIENCE. To serve the interest of both practicing clinicians and researchers, the journal provides platform or forum for research scholars, intellectuals, and cardiologists to reveal their views and research work for dialogue, education, and interaction to the entire world. HEART SCIENCE publishes original research, reviews, brief reports, case reports, case series, editorial, and commentary. HEART SCIENCE also publishes the special issues and abstracts of papers presented at the annual meeting of the Cardiological Society of Malang.
Arjuna Subject : Kedokteran - Cardiology and Cardiovascular Medicine
Articles 302 Documents
 16   17   18   19   20 
The role of exercised-based cardiac rehabilitation in unrevascularized complex coronary artery disease patients: a case series Aryanugraha, Teguh; Tjahjono, Cholid Tri; Mayangsari, Veny; Satrijo, Budi; Anjarwani, Setyasih
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.13

Abstract

Background: Coronary artery disease (CAD) is a common type of heart disease that elevates the risk of morbidity and mortality significantly. Although revascularization techniques like coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are advised for CAD patients, some people may not be eligible for or choose not to undergo revascularization. Even though cardiac rehabilitation (CR) enhances cardiovascular outcomes, quality of life, and general well-being, the utilization of CR is still very low.Case illustration: The first patient was a 72-year-old man, and the second patient was a 60-year-old man. They were referred for CR after refusing revascularization, and both are left-main and three-vessel disease patients. The first patient underwent CR for six months and the second patient for 18 months, then the Six Minutes Walking Test (6MWT) and 36-Item Short Form Health Survey (SF-36) were performed before and following CR. The evaluation is an increase in walking distance and patient quality of life.Conclusion: By enhancing quality of life, exercised-based CR programs offer an approach to managing CAD, especially in those who may not be suitable candidates for or choose to avoid revascularization procedures.
Exploring the efficacy of al-hijamah (wet cupping) in managing hypertension and dyslipidemia among Indonesian population: a meta-analysis Aulya, Justika Usmadhani; Matondang, Asri Rizqi; Farahdina, Farahdina; Rizaliansyah, Ferdian; Samsu, Nur; Fajar, Jonny Karunia
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.8

Abstract

BACKGROUND: In Indonesia, wet cupping therapy has been thoroughly investigated as a treatment for hypertension and dyslipidemia. Nevertheless, the outcomes across these studies are contradictory.OBJECTIVES: To appraise the effectiveness of wet cupping therapy in the management of hypertension and dyslipidemia among the Indonesian population.METHODS: We examined papers sourced from Google Scholar, the Indonesian Scientific Journal Database, and Garba Rujukan Digital until September 5, 2020. These papers investigated blood pressure and lipid profile levels both pre- and post-wet cupping treatment. The collective data underwent Z-test analysis to assess associations.RESULTS: In total, we included 26 papers examining the correlation between wet cupping therapy and blood pressure, as well as 16 papers assessing lipid profile levels. Our combined analysis revealed significantly reduced systolic blood pressure (MD: 13.86; 95% CI: 10.01, 17.71), diastolic blood pressure (MD: 6.31; 95% CI: 3.84, 8.79), and lower total cholesterol levels (MD: 21.56; 95% CI: 10.32, 32.80]) in the post-treatment group compared to the pre-treatment group. However, we were unable to elucidate the impact of wet cupping therapy on the concentrations of low-density lipoprotein and triglyceride.CONCLUSIONS: Wet cupping therapy exhibits potential efficacy in reducing blood pressure and total cholesterol levels among individuals in Indonesia.
The role of colchicine on ventricular remodelling following myocardial infarction and ischemia-reperfusion injury: article review Caesario, Fahreza; Prasetya, Indra
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.3

Abstract

Acute myocardial infarction (AMI) is a major cause of cardiac dysfunction, arrhythmias, and a poor prognosis. Even though new technologies have been developed to aid in opening the culprit coronary artery and correcting ischemia-related stenosis by percutaneous coronary intervention (PCI), the ventricular remodelling that induces cardiac failure as a consequence of AMI remains unchanged. Colchicine, a versatile anti-inflammatory medication, has been documented in mitigating cardiac remodelling and enhancing cardiac function following AMI. This article provides an in-depth review of the processes by which colchicine affects ventricular remodeling after AMI, highlighting the potential role of inflammation in the pathogenesis and progression of ventricular dysfunction.
A case report: successful percutaneous coronary intervention (PCI) in unprotected left main and three-vessel coronary artery disease Kahadi, Cik; Rohman, Mohammad Saifur
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.14

Abstract

Background: Left Main Coronary Artery (LMCA) Disease is the highest-risk lesion of coronary artery disease and is related to cardiovascular morbidity and mortality compared to other types of obstructive Coronary Arterial Disease (CAD). Previously, coronary artery bypass grafting (CABG) was the preferred method for revascularization in significant LMCA lesions; however, results from several trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) to CABG showed PCI was non-inferior to CABG in highly selected LMCA patients. This report was to describe the contemporary evidence for PCI to CABG in LMCA Disease.Case Presentation: A diabetic and hypertensive 59-year-old man with stable angina pectoris and Canadian Cardiovascular Society (CCS) Score III was referred to Saiful Anwar Hospital for elective PCI consideration. The patient was diagnosed with left main and three-vessel coronary artery disease from CCTA in 2009 and angiography in 2023, then suggested to CABG for revascularization. However, the patient refused CABG surgery and decided to perform PCI with high-risk criteria after an adequate consultation. Considering the high-risk category and reduced ejection fraction, an elective PCI was performed with intra-aortic balloon pump (IABP) support. Then it implanted 2 DES at distal-LM until distal-LCx. In the following procedure, the patient also implanted 1 DES at mid-distal RCA and was discharged with significant improvement in his quality of life.Conclusion: In selected left main and three-vessel coronary artery disease, PCI is successfully improves the patient's quality of life
Effect of β-1,3-1,6-D-glukan (polysaccharide peptide) from miselia ganoderma lucidum extract as antioxidant and antiinflammation towards left ventricular systolic function in cardiometabolic patients Aryanugraha, Teguh; Sargowo, Djanggan; Rahimah, Anna Fuji
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.9

Abstract

Background: Cardiometabolic disease (CMD) describes a metabolic condition often associated with cardiovascular disease. It has been revealed that the Ganoderma lucidum polysaccharide peptide (GLPP) possesses anti-inflammatory and antioxidant qualities. Objective: This study aimed to find out how GLPP affected oxidative stress, inflammation, and left ventricular function in individuals with cardiometabolic syndrome.Methods: A multicenter double-blinded randomized controlled trial was carried out. Subjects with cardiometabolic syndrome received either GLPP or a placebo for ninety days. Before taking the initial treatment and one day following the last treatment intake, blood samples were taken from every participant. The enzyme-linked immunosorbent assay was used to evaluate the levels of serum tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), malondialdehyde (MDA), and high-sensitivity-C-Reactive Protein (hs-CRP) while the colorimetric test was used to measure the levels of superoxide dismutase (SOD). Global longitudinal strain (GLS)  and Left ventricle ejection fraction (LVEF) were measured by single echocardiographer expert validation.Results: The MDA level was decreased in the GLPP treatment group (mean 56.0 ± 71.4 ng/mL to 27.7 ± 12.0 ng/mL, p= 0.023) compared to the control group (mean 39.3 ± 29.2 ng/mL to 38.3 ± 17.7 ng/mL, p= 0.719). However, the SOD level remained constant in the GLPP treatment (mean 122.2 ± 176.1 U/mL to 93.0 ± 40.9 U/mL, p=0.925) instead of significantly declining in the control group (mean 102.0 ± 67.3 U/mL to 64.0 ± 52.0 U/mL, p=0.016). The marker of TNF-α and hsCRP were significantly decreased in all groups (both p<0.05), but IL-6 was only significantly decreased in the control group (mean 1149.3 ± 581.7 pg/mL to 744.8 ± 336.5 pg/mL, p=0.010). The GLS was significantly decreased in the GLPP treatment group (-16.1 ± 4.1 to -17.5 ± 4.8, p=0.048) but there was no difference in LVEF in both groups (p>0.05).Conclusion: Patients with cardiometabolic syndrome may benefit from GLPP treatment for 90 days in terms of reduced inflammation, oxidative stress, and improved systolic left ventricular performance.
Cardiac rehabilitation and prescription exercise training for heart failure’s patients Fathurohim, Zainal; Tjahjono, Cholid Tri
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.4

Abstract

Cardiovascular rehabilitation is a multidisciplinary approach that includes exercise instruction, reduction of cardiac risk factors, psychosocial assessment, and result evaluation. Cardiovascular rehabilitation (CR), which includes exercise training, has been shown to significantly improve people with heart failure's quality of life, functional ability, and hospitalizations for heart failure-related conditions. There are so many benefits that are crucial for patients that they must be implemented fully in every health center. The objective for all healthcare practitioners must be to include CR in the regular, normal management of HF patients.
How to decide appropriate percutaneous coronary intervention (PCI) technique for managing heavy calcified coronary lesions: serial case-report Caesario, Fahreza; Rohman, Mohammad Saifur
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.15

Abstract

Background: Coronary artery calcification (CAC) is still challenging for interventional cardiologists. Their contribution to major adverse cardiac events occurs from the high risk of stent thrombosis or in-stent restenosis and target lesion revascularization. Optimal preparation, such as coronary plaque modification before stenting, is required to reduce the risk of periprocedural adverse events. This case presentation aimed to describe the appropriate management of heavy calcified coronary lesions.Case Presentation: Two cases of heavy calcified coronary lesions with different baselines as Acute Coronary Syndromes (ACS) and elective PCI were presented. In our ACS patients, the Primary PCI was done by coronary angioplasty without stenting because of the complexity of the heavily calcified lesion. A referral to tertiary health care was made for further PCI procedures using a combination of calcium-ablation and balloon-based techniques. A treatable complication occurred after the orbital atherectomy was performed with good results. The second case was an elective PCI patient with heavy calcified lesions findings from coronary angiography. The balloon-based technique was performed using non-compliant and scoring balloons without complication and showed good results.Conclusion: The challenging points in managing heavy calcified coronary lesions are procedure complexity and the higher stent failure rate. Many modifying coronary calcification algorithms using advanced modalities have been proposed, which could be used to select the appropriate technique as experienced and increase the success rate.
Correlation between HbA1c levels and intrastent restenosis incidence in patients with diabetes mellitus after percutaneous coronary intervention at Dr. Saiful Anwar General Hospital Millisani, Hayla Iqda; Prasetya, Indra; Rohman, Mohammad Saifur
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.10

Abstract

Background: Patients with chronic uncontrolled diabetes mellitus as indicated by HbA1c levels ≥ 6.5%, increase the risk of atherosclerosis, thereby increasing in-stent restenosis incidence during and after percutenous coronary intervention. Regular monitoring of HbA1c is crucial to reduce the incidence of in-stent restenosis.Objective: This study aims to ascertain the correlation between HbA1c levels and in-stent restenosis incidence in diabetes mellitus patients after percutenous coronary intervention at Dr. Saiful Anwar General Hospital, Malang, East Java, Indonesia.Methods/Design: Analytical observational study with a retrospective cohort study approach to determine the correlation between HbA1c levels and the incidence of in-stent restenosis in patients with diabetes mellitus after percutenous coronary intervention. The research sample was carried out by consecutive sampling in January 2021-December 2023.Results: This study has recruited 555 patients with coronary artery disease and diabetes mellitus. The average age of coronary heart disease patients with diabetes mellitus was 59 years. Patients with HbA1c levels ≥6.5 were more prone to experience in-stent restenosis 54 patients, while those with HbA1c levels <6.5 were more prone not to experience in-stent restenosis 388 patients, indicating a significant correlation between HbA1c and in-stent restenosis p=0.024. in-stent restenosis was most frequently observed in the LAD 44 patients, RCA 13 patients, LCx 10 patients, and LM 0 patient. The highest percentage of in-stent restenosis cases was over 70%, with 3VD lesions being the most common 55 patients. OAD therapy is most often given to coronary heart disease patients with diabetes mellitusConclusion: There is a correlation between HbA1c levels and the incidence of in-stent restenosis in diabetes mellitus patients after percutaneous coronary intervention, underscoring the necessity for routine blood glucose monitoring to prevent in-stent restenosis.
SGLT2 inhibitor, a new bullet in heart failure management Saidi, Zaki; Widito, Sasmojo
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.5

Abstract

The global health landscape is confronted with substantial challenges stemming from diabetes mellitus and heart failure (HF). The escalating incidence of diabetes mellitus (DM), in correlation with HF, underscores the imperative necessity for efficacious strategies in the realm of prevention and management. The most recent advancements in therapeutic approaches, specifically Sodium-glucose transporter 2 inhibitors (SGLT2i), present a promising prospect for enhancing outcomes and addressing the existing gaps in HF management. This paper aims to elucidate the significance of SGLT2i in the therapeutic management of both reduced and preserved heart failure, with or without the presence of DM. SGLT2i are new heart failure drugs. In trials, SGLT2i improved diastolic dysfunction, reduced oxidative stress, inflammation, fibrosis, and myofilament rigidity. The first SGLT2 inhibitor studies, EMPA-REG OUTCOME, DECLARE-TIMI 58, and CANVAS, showed that Empagliflozin and Canagliflozin reduced HF mortality and rehospitalization in type 2 diabetes mellitus (T2DM) patients. Dapagliflozin reduces HF hospitalizations without impacting T2DM mortality. Canagliflozin avoided creatinine rises, kidney disease deaths, and cardiovascular deaths in the CREDENCE Study. SGLT2i improve health in heart failure with preserved ejection fraction (HFpEF). SGLT2i improved health status statistically in the PRESERVED-HF and EMPEROR-Preserved investigations. SGLT2i became known as a promising therapeutic choice in the treatment of HF. The substantial evidence from prominent large-scale clinical trials has substantiated the cardiovascular and renal protective effects of SGLT2i. Furthermore, the benefits of these medications are relevant for individuals who have been diagnosed with heart failure with reduced ejection fraction (HFrEF), as well as those who are experiencing heart failure with preserved ejection fraction (HFpEF).
Carbon dioxide (CO2) as an alternative contrast agent in percutaneous transluminal angioplasty procedures for chronic limb-threatening ischemia patients with chronic kidney disease Vori, Ira; Kurnianingsih, Novi
Heart Science Journal Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2024.005.04.16

Abstract

Background: Chronic limb-threatening ischemia (CLTI) is a very morbid illness that significantly reduces quality of life. The severity of this disease may necessitate revascularization or amputation.Arteriography is frequently performed for the planning of revascularization. Patients with compromised kidney function need alternative contrast agents.CO2 may be utilized in lower extremity vascular diagnostics and intervention, especially in patients at risk for contrast-induced nephropathy (CIN).Case Illustration: An 80-year-old female with bilateral leg pain and leg swelling had an ulcer on her toe for 2 weeks. She had a history of intermittent claudication for 1 year, hypertension for 5 years, kidney stones for 2 years, and chronic kidney disease for 1 year. She underwent an ECG, laboratory, USG, DUS, and CT-angiography examination. From her laboratory result, her initial creatinine was 5.02 mg/dL (eGFR 8 mL/m/1.73 m2). After good hydration, it became 1.28 mg/dL (eGFR 39 mL/m/1.73 m2). After a CT-angiography procedure, her creatinine level was increased (3.7 mg/dL; eGFR 10.9 mL/m/1.73 m2). She was diagnosed with CLTI Rutherford V Fontain 3 left lower extremity. She suggested doing an angioplasty procedure with a safer contrast agent. An angioplasty procedure was done at RSSA Malang with CO2 contrast. After the procedure, her leg pain improved, and her creatinine didn’t elevate.Conclusion: CO2 angiography might be used as a safe alternative contrast medium in patients with CLTI, which benefits the preservation of renal function and prevents limb amputations.

Page 18 of 31 | Total Record : 302

 16   17   18   19   20 

Filter by Year

2020 2025


Reset
Filter By Issues
All Issue Vol. 6 No. 4 (2025): The Pursuit of Precision: Navigating Risks, Refining Diagnosis, and Securing Lo Vol. 6 No. 3 (2025): Advancements in Cardiac Imaging : Unlocking New Perspectives on the Heart Visua Vol. 6 No. 2 (2025): The Complexity in the Management of Heart Rhythm Disorder Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure Vol. 6 No. Suppl_July (2025): Supplement Issue : Indonesian Acute Coronary Syndrome Summit in Conjun Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease Vol. 5 No. 3 (2024): The Science and Art of Revascularization in Acute Coronary Syndrome Vol. 5 No. 2 (2024): Challenges in the Management of Congenital Heart and Structural Heart Diseases Vol. 5 No. 1 (2024): Inflammation and Cardiovascular Disease Vol. 4 No. 4 (2023): The Science and Art of Caring for Critically III Patients in Intensive Cardiac Vol. 4 No. 3 (2023): The Essensial Role of the Metabolic Syndrome in the Development of Cardiovascul Vol 4, No 2 (2023): Dealing with the Complexity of the Wide Spectrum of Cardiovascular Disease Vol. 4 No. 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol 4, No 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol. 3 No. 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improv Vol 3, No 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improve Vol. 3 No. 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 2 (2022): Improving ST-Elevation Myocardial Infraction Patients Prognosis Vol 3, No 1 (2022): Assesment and Outcome of Coronary Artery Disease in the Reperfusion Era Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease Vol 2, No 3 (2021): The Science and Art of Myocardial Revascularization Vol 2, No 2 (2021): Dealing with Vascular Disease Vol 2, No 1 (2021): How to Diagnose Heart Failure and Deal with The Treatment Complexity Vol 1, No 4 (2020): Acute Coronary Syndrome in Daily Practice : Diagnosis, Complication, and Managem Vol 1, No 3 (2020): Management of Coronary Artery Disease: From Risk Factors to The Better Long-Term Vol 1, No 2 (2020): The Assessment of Diagnostic and Treatment Modality in Heart Failure Vol 1, No 1 (2020): The Importance of Adherence to The Guidelines More Issue